Clinical Trial Update: Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nimotuzumab in combination with docetaxel for advanced non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Biotech Pharmaceutical Co., Ltd. | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED